Bertis
- Company typePrivate
- Founded2014
- HeadquartersSeongnam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
Bertis firmographics
Firmographics- Name
- Bertis
- Legal name
- BERTIS Inc
- Website
- https://bertis.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Bertis industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Proteomics & Mass Spectrometry Services (HLAGANAB)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Bertis is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Bertis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- MASTOCHECK Diagnostic Tests: Sales of breast cancer early detection blood tests through hospitals, medical checkup centers, and diagnostic laboratories. Revenue generated per test through distribution agreements with healthcare providers in Korea and internationally.
- PASS (Pan-omics Analysis Service & Solution): B2B proteomics analysis services provided to pharmaceutical companies and biotech firms for biomarker discovery, drug development research, and companion diagnostics. Revenue generated through project-based contracts and analysis service fees.
- Diagnostic Pipeline Products: Future revenue expected from PANCCHECK (pancreatic cancer), OVACHECK (ovarian cancer), and next-generation Mastocheck2 products currently under development and clinical trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | MASTOCHECK breast cancer screening test |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
Bertis product offering
Product offeringCore offering
Bertis is a proteomics-based molecular diagnostics company that commercializes the world's first proteomics-based breast cancer early detection blood test (MASTOCHECK®) and provides pan-omics analysis services (PASS) to pharmaceutical and biotech companies for drug discovery and biomarker research. Its proprietary quantitative proteomics platform leverages mass spectrometry and AI to identify disease-related protein panels for cancer diagnostics and translational research.
Differentiator
Problem solved
Functional benefit
Brands
- MASTOCHECK: World's first proteomics-based breast cancer early detection blood test
- PASS
- DEEP-find
- CHECK series
Products and services
- MASTOCHECK® Proteomics-based blood test for early detection of breast cancer, requiring only 1 ml of blood with no radiation exposure. Approved for stage 0-2 breast cancer diagnosis at 92% accuracy. Effective for women with dense breast tissue, young women aged 20-30, and pregnant women. Distributed through 550+ hospitals and medical checkup centers in Korea and through channel partners across Southeast Asia.
- PASS (Pan-omics Analysis Service & Solution) Customer-customized proteomics analysis service for pharmaceutical companies and biotech firms, providing comprehensive proteome and phosphoproteome profiling for biomarker discovery, drug mechanism studies, and companion diagnostics. Utilizes Orbitrap Astral mass spectrometer with proprietary COFFER fractionation technology identifying over 10,000 proteins per sample.
Quantifiable outcome
- 92% accuracy for 0-2 stage breast cancer diagnosis using 3-biomarker algorithm
- +4 more outcomes
Companies that use Bertis
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles1 record
Bertis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature8 records
Bertis partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered significant, core, flagship, major and strategic.
- Fraunhofer IZIsignificantOctober 2019 MOU for global joint R&D on proteomics-based early diagnosis solutions. Collaboration includes comparing tumor marker expression between European and Asian patients, serum tumor marker investigation, early diagnosis prediction algorithms, and therapeutic peptide development.
- MedicalIPsignificantMarch 2021 MOU for developing bio-dual compound AI platform using medical imaging data and quantitative proteomics. Aims to predict and prevent diseases through integrated analysis of genomic, proteomic, and medical imaging data (CT, MRI, X-ray).
- Seoul National University Bundang HospitalcoreApril 2021 MOU for blood plasma proteomics analysis research. Collaboration on sex and age-based blood protein profiling and protein biomarker discovery for personalized health monitoring.
- National Cancer Center KoreacoreDecember 2021 MOU for proteomics-based cancer diagnosis and treatment technology R&D. Includes proteomics biomarker research using tissue and blood samples, and clinical trial collaboration for next-generation cancer diagnostics and therapeutics.
- Vanderbilt University Medical Center (VUMC)flagshipMarch 2026 joint research contract for AI-based drug target discovery. Bertis applies its AI-based drug target discovery platform to VUMC's spatial omics research, combining DEEP-find™ with VUMC's spatial omics tissue analysis. Focus on HER2-low tumors initially, expanding to various cancer types.
- Innoquest Diagnostics / Pathology Asia GroupcoreJuly 2025 supply agreement with Singapore's largest clinical diagnostic laboratory. Strengthens Singapore testing infrastructure and enables expansion to Indonesia, Malaysia, Thailand, Vietnam, Philippines, Australia, and Hong Kong (7 countries).
- Raffles Medical GroupmajorSeptember 2022 supply agreement with Singapore's largest private healthcare group. MASTOCHECK deployed through Raffles Breast Centre, Raffles Health Screeners, and 30+ medical institutions. Future expansion planned to China, Japan, Cambodia, Vietnam.
- LifeStrandsmajorJanuary 2025 supply agreement for MASTOCHECK sales and marketing in Thailand and Philippines. LifeStrands is a genomics subsidiary of Pathology Asia Group leveraging hospital networks across 5 countries.
- CosmaxsignificantApril 2025 MOU for skin proteomics analysis research cooperation. Collaboration includes skin protein analysis technology development, joint biomarker panel development, and cosmetics ingredient formulation and commercialization.
- E&CellsignificantJuly 2021 MOU for developing next-generation breast cancer cell therapy using proteogenomic analysis technology. Bertis analyzes breast cancer subtypes using its proteogenomic technology, combined with E&Cell's cell therapy development capabilities for subtype-specific new drug candidate discovery.
- Rockit GenomicsstrategicAugust 2024 MOU for single-cell proteomics and genomics analysis service collaboration. Bertis provides single-cell proteomics analysis services while Rockit Genomics offers single-cell genomic sequencing, enabling multi-omics analysis services and joint technology development.
- Ulsan National Institute of Science and TechnologystrategicSeptember 2024 joint participation in Ministry of Science and ICT 'Spatial Proteomics Multi-omics Analysis Technology Development' project. 4.5-year project with 9 billion KRW research budget involving 6 institutions. Bertis develops LC-MS analysis conditions for single cells and spatial proteomics-specific preprocessing materials.
- MetaBioTechstrategicCo-research partner in spatial proteomics technology development project. Developing protein peptidization materials and source technology, aiming to establish global-first analysis platform from tissue separation to diagnosis.
- Korea Basic Science InstitutestrategicPartner in spatial proteomics multi-omics technology development project led by Ulsan National Institute of Science and Technology.
- Bundang CHA Hospital Future Medicine InstitutestrategicPartner in spatial proteomics multi-omics technology development project, contributing to database construction and AI software development for cancer-type specific biomarkers.
Scale indicators8 records
Recent moves8 records
Expansion highlights7 records
Bertis competitors and assessment
Company assessmentDirect peers
- SomaLogic: US proteomics company operating the SomaScan platform for large-scale protein measurement, serving pharma R&D and clinical diagnostics applications. Direct peer in protein biomarker discovery and clinical proteomics services.
- Personalis: US cancer genomics/proteomics company providing molecular diagnostics and biomarker analysis for pharma and clinical customers. Direct peer in deep molecular profiling services for oncology.
- Guardant Health: US liquid biopsy leader (Guardant360, Guardant Shield) using blood-based molecular diagnostics for cancer detection and monitoring. Direct peer in blood-based cancer screening diagnostics.
- Olink Holding: Sweden-based proteomics company offering high-throughput protein biomarker discovery platforms (PEA technology) used widely in pharma research and clinical studies. Closely comparable in customer base (pharma/biotech) and biomarker analytical services, though with a different technology foundation.
- Seer: US-based proteomics company using mass spectrometry for deep, unbiased proteomic profiling. Direct peer in the proteomics platform business serving pharma/biotech researchers, similar to Bertis's PASS offering.
- GRAIL: US multi-cancer early detection company (Galleri test) developing blood-based screening for multiple cancers. Direct peer in early-stage, blood-based multi-cancer screening.
Broad incumbents
- Exact Sciences: US diagnostics leader (Cologuard for colorectal cancer screening, Oncotype DX). Broad incumbent in non-invasive cancer screening diagnostics with overlapping technology platform approach.
- NeoGenomics: US clinical cancer diagnostics laboratory offering oncology-focused testing services across multiple modalities. Broader incumbent in cancer diagnostics with overlapping biomarker discovery and clinical testing services.
Regional players
- Seegene: Korea-based molecular diagnostics company specializing in multiplex PCR technologies for infectious disease and oncology. Regional peer from the same Korean diagnostics ecosystem with comparable hospital distribution model.
- Macrogen: Korea-based genomics and precision medicine company providing sequencing services and molecular diagnostics. Regional peer operating in Korea with similar B2B services model and Asia-focused expansion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks2 records
Key highlights7 records
Customer concentration
Bertis social profiles
Digital presenceBertis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bertis leadership team
Management profileNumber of profiles
Profiles8 records
Bertis subsidiaries and ownership
Company hierarchySubsidiaries2 records
Bertis funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bertis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bertis
What does Bertis do?
Bertis is a proteomics-based molecular diagnostics company that commercializes the world's first proteomics-based breast cancer early detection blood test (MASTOCHECK®) and provides pan-omics analysis services (PASS) to pharmaceutical and biotech companies for drug discovery and biomarker research. Its proprietary quantitative proteomics platform leverages mass spectrometry and AI to identify disease-related protein panels for cancer diagnostics and translational research.
Is Bertis a public or private company?
Bertis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bertis founded?
Bertis was founded in 2014. It employs 11 to 50 people.
Where is Bertis based?
Bertis is headquartered in Seongnam, South Korea, in the Asia region.
How does Bertis make money?
Three revenue lines are on record. MASTOCHECK Diagnostic Tests are the primary driver. The others are PASS (Pan-omics Analysis Service & Solution) and diagnostic Pipeline Products.
Who are Bertis's main competitors?
Direct peers on record are SomaLogic, Personalis, Guardant Health, Olink Holding, Seer and GRAIL. Broad incumbents are Exact Sciences and NeoGenomics. Regional players are Seegene and Macrogen.
Does Bertis have an API?
No public API is recorded for Bertis.
What industry is Bertis in?
Bertis's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2835.